Calquence® (acalabrutinib) – New drug approval
October 31, 2017 – The FDA announced the approval of AstraZeneca’s Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Download PDF
